Wie hoch ist der Preis für OptiNose, Inc. (OPTN)

Preis für OptiNose, Inc. (OPTN) ist $9.60

Wie hoch ist die Marktkapitalisierung für OptiNose, Inc. (OPTN)

Marktkapitalisierung für OptiNose, Inc. (OPTN) ist $1.08B

OptiNose, Inc. (OPTN) Aktiensplits

OptiNose, Inc. is a specialized pharmaceutical company primarily focused on innovating and bringing to market treatments for individuals under the care of ear, nose, throat, and allergy specialists throughout the United States. Its flagship product, XHANCE, utilizes the company's proprietary exhalation delivery system (EDS) to administer a topically-acting corticosteroid. This therapy is approved for treating chronic rhinosinusitis when accompanied by nasal polyps and is currently undergoing Phase IIIb clinical trials for broader chronic sinusitis treatment. The company also offers Onzetra Xsail, a powder-based EDS device, which is commercialized via a licensing agreement with Currax Pharmaceuticals LLC. Further expanding its pipeline, OptiNose is developing OPN-019, an investigational product that integrates a liquid EDS device with an antiseptic agent. Additionally, OptiNose has formed a partnership with Inexia Limited. This collaboration centers on the development, manufacturing, importation, and sale of products containing orexin receptor agonist or positive modulator molecules, intended for the treatment, diagnosis, or prevention of human conditions predominantly linked to orexin receptor activity. Established in 2000, OptiNose, Inc. operates from its corporate headquarters in Yardley, Pennsylvania.

Jahr	Aktien-Split	Multiplikator	Kumulierter Multiplikator
2024-12-31	1:15	x0.066666666666667	x0.066666666666667

Jahr

Aktien-Split

Multiplikator

Kumulierter Multiplikator

2024-12-31

1:15

x0.066666666666667

Unternehmen	Anzahl der Aktiensplits	Kumulierter Multiplikator	Land
MERCK Kommanditgesellschaft auf Aktien MER.SW	0	-	DE
Merck KGaA MRK.DE	0	-	DE
Takeda Pharmaceutical Company Limited 4502.T	0	-	JP
Galderma Group AG GALD.SW	0	-	CH
Sun Pharmaceutical Industries Limited SUNPHARMA.NS	5	x119	IN

Unternehmen

Anzahl der Aktiensplits

Kumulierter Multiplikator

Land